Stock Analysis on Net

Abbott Laboratories (NYSE:ABT)

Balance Sheet: Assets
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

Abbott Laboratories, consolidated balance sheet: assets (quarterly data)

US$ in millions

Microsoft Excel
Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Cash and cash equivalents 7,616 7,558 6,987 6,284 6,896 6,709 7,835 9,161 9,882 9,594 8,937 7,675 9,799 9,302 8,658 8,054 6,838 4,480 4,763 3,377
Short-term investments 351 230 232 367 383 338 320 371 288 313 353 483 450 390 286 318 310 251 274 291
Trade receivables, less allowances 6,925 7,051 6,854 6,605 6,565 6,499 6,172 6,020 6,218 6,408 7,199 7,179 6,487 6,405 6,113 6,096 6,414 5,649 5,140 5,292
Finished products 3,700 4,173 4,060 4,063 3,946 3,847 4,004 3,944 3,805 3,407 3,570 3,470 3,081 3,048 3,118 3,219 3,030 3,173 3,240 2,873
Work in process 840 877 880 881 807 888 845 805 680 726 710 695 694 710 796 773 712 721 675 615
Materials 1,654 1,763 1,874 1,883 1,817 1,915 2,022 1,924 1,688 1,601 1,619 1,526 1,382 1,503 1,525 1,395 1,270 1,258 1,287 1,080
Inventories 6,194 6,813 6,814 6,827 6,570 6,650 6,871 6,673 6,173 5,734 5,899 5,691 5,157 5,261 5,439 5,387 5,012 5,152 5,202 4,568
Prepaid expenses and other receivables 2,570 2,150 2,232 2,293 2,256 2,468 2,307 2,152 2,663 2,796 2,568 2,401 2,346 2,134 2,131 1,962 1,867 1,858 1,842 1,970
Current assets 23,656 23,802 23,119 22,376 22,670 22,664 23,505 24,377 25,224 24,845 24,956 23,429 24,239 23,492 22,627 21,817 20,441 17,390 17,221 15,498
Investments 886 912 877 818 799 788 799 776 766 764 734 763 816 812 805 832 821 803 776 790
Property and equipment, at cost 22,740 22,857 22,061 22,055 21,933 21,111 20,926 20,605 20,212 19,306 19,458 19,521 19,364 19,182 19,074 18,697 18,793 17,972 17,374 16,707
Accumulated depreciation and amortization (12,082) (12,236) (11,828) (11,948) (11,779) (11,559) (11,477) (11,323) (11,050) (10,617) (10,640) (10,613) (10,405) (10,351) (10,258) (9,865) (9,764) (9,352) (9,031) (8,800)
Net property and equipment 10,658 10,621 10,233 10,107 10,154 9,552 9,449 9,282 9,162 8,689 8,818 8,908 8,959 8,831 8,816 8,832 9,029 8,620 8,343 7,907
Intangible assets, net of amortization 6,647 7,352 7,827 8,296 8,815 9,282 9,834 10,006 10,454 10,850 11,592 12,225 12,739 13,312 13,681 14,181 14,784 15,208 15,783 16,265
Goodwill 23,108 23,658 23,308 23,383 23,679 23,277 23,258 22,927 22,799 22,284 22,744 23,179 23,231 23,299 23,485 23,384 23,744 23,338 23,082 22,927
Deferred income taxes and other assets 16,459 8,011 7,653 7,487 7,097 6,527 6,509 6,426 6,033 5,369 5,358 5,503 5,212 4,049 3,855 3,739 3,729 3,684 3,571 3,390
Long-term assets 57,758 50,554 49,898 50,091 50,544 49,426 49,849 49,417 49,214 47,956 49,246 50,578 50,957 50,303 50,642 50,968 52,107 51,653 51,555 51,279
Total assets 81,414 74,356 73,017 72,467 73,214 72,090 73,354 73,794 74,438 72,801 74,202 74,007 75,196 73,795 73,269 72,785 72,548 69,043 68,776 66,777

Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).


Assets: Selected Items

Balance sheet item Description The company
Current assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Abbott Laboratories current assets increased from Q2 2024 to Q3 2024 but then slightly decreased from Q3 2024 to Q4 2024.
Net property and equipment Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. Abbott Laboratories net property and equipment increased from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024.
Long-term assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Abbott Laboratories long-term assets increased from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024.
Total assets Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Abbott Laboratories total assets increased from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024.

Current Assets: Selected Items

Balance sheet item Description The company
Cash and cash equivalents Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Abbott Laboratories cash and cash equivalents increased from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024.
Short-term investments Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. Abbott Laboratories short-term investments decreased from Q2 2024 to Q3 2024 but then increased from Q3 2024 to Q4 2024 exceeding Q2 2024 level.
Trade receivables, less allowances Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. Abbott Laboratories trade receivables, less allowances increased from Q2 2024 to Q3 2024 but then slightly decreased from Q3 2024 to Q4 2024 not reaching Q2 2024 level.
Inventories Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. Abbott Laboratories inventories decreased from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024.